455 East Medical Center Boulevard
Suite 300
Houston, TX 77598
United States
281 651 5150
https://www.fibrobiologics.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 10
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Peter O'Heeron | Founder, Chairman & CEO | 884,39k | S.O. | 1964 |
Mr. Mark C. Andersen C.F.A., CPA, M.B.A. | Chief Financial Officer | 429,65k | S.O. | 1972 |
Dr. Hamid Khoja Ph.D. | Chief Scientific Officer | 393,6k | S.O. | 1970 |
Mr. Ruben A. Garcia | General Counsel | S.O. | S.O. | 1977 |
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
L’ISS Governance QualityScore de FibroBiologics, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..